Holen Sie sich die Stockscreener-App
7.03
3.17%
-0.23
Handel nachbörslich:
7.02
-0.01
-0.14%
Schlusskurs vom Vortag:
$7.26
Offen:
$7.29
24-Stunden-Volumen:
446.01K
Relative Volume:
0.35
Marktkapitalisierung:
$335.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.85M
KGV:
-7.9372
EPS:
-0.8857
Netto-Cashflow:
$-54.54M
1W Leistung:
-2.09%
1M Leistung:
+23.99%
6M Leistung:
+212.44%
1J Leistung:
+428.57%
1-Tages-Spanne:
$6.83
$7.4465
1-Wochen-Bereich:
$6.83
$8.04
52-Wochen-Spanne:
$1.05
$8.04
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
7.03 | 346.80M | 0 | -59.85M | -54.54M | -0.8857 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Wedbush | Outperform |
| 2026-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Analysts’ Weekly Ratings Updates for Climb Bio (CLYM) - Defense World
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Research Analysts Issue Forecasts for Climb Bio Q1 Earnings - Defense World
Climb Bio (NASDAQ:CLYM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for Climb Bio Issued By HC Wainwright - MarketBeat
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline - Investing.com UK
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $15.00 - MarketBeat
Climb Bio (NASDAQ:CLYM) Research Coverage Started at Wedbush - Defense World
Published on: 2026-03-08 04:23:03 - baoquankhu1.vn
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Fed Meeting: Is Climb Bio Inc a stock for growth or value investors2025 Biggest Moves & Consistent Income Trade Ideas - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Wedbush Raises Price Target for CLYM, Maintains 'Outperform' Rat - GuruFocus
Baird Maintains "Outperform" Rating, Raises Price Target for CLY - GuruFocus
Climb Bio (NASDAQ:CLYM) Price Target Raised to $12.00 - MarketBeat
Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis
Investment Recap: What is the Moat Score of Climb Bio Inc2025 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Wedbush Begins Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Wedbush initiates Climb Bio stock with Outperform rating By Investing.com - Investing.com Nigeria
Wedbush initiates Climb Bio stock with Outperform rating - Investing.com India
Wedbush Initiates Climb Bio at Outperform With $12 Price Target - marketscreener.com
Climb 2025 10-K: $0 Revenue, $(0.88) EPS and $59.9M Net Loss - TradingView
CLYM: Net loss narrowed to $59.9M in 2025 as clinical R&D spending accelerated - TradingView
Aug PostEarnings: Does Climb Bio Inc offer margin of safetyJuly 2025 Highlights & Detailed Earnings Play Alerts - baoquankhu1.vn
CLYM Stock Price and Chart — NASDAQ:CLYM - TradingView
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell Alert: Stephen Thomas Sells 50,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (NASDAQ:CLYM) Reaches New 12-Month HighStill a Buy? - MarketBeat
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference - MarketBeat
Climb Bio (CLYM) Price Target Increased by 20.30% to 11.66 - Nasdaq
Proposed 50,000-share sale by CLYM broker (CLYM) - Stock Titan
CLYM: Multiple clinical readouts expected in 2024 for antibody therapies in PMN, ITP, and IgAN - TradingView
CLYM: Five clinical data readouts expected in 2024, with cash runway secured into 2028 - TradingView
Aug Update: What is Fresh Del Monte Produce Incs 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
CLYM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Climb Bio’s Stock Run Puts All Eyes On 2026 Trial Data - Finimize
Klein Hersh Recruits Chief Medical Officer for Zag Bio - Hunt Scanlon Media
Climb Bio (CLYM) director sells 100,000 shares in planned trades - Stock Titan
What’s the analyst consensus on Climb Bio Inc.Earnings Beat & Verified Short-Term Trading Plans - mfd.ru
This Taiwan Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit - MarketBeat
Piper Sandler initiates Climb Bio stock with Overweight rating, $23 target - Investing.com Canada
CLYM: Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress - TradingView
CLYM (NASDAQ: CLYM) shareholder files to sell 100,000 shares - Stock Titan
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Sahm
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):